Based on the Extendicare Inc stock forecast from 3 analysts, the average analyst target price for Extendicare Inc is CAD 9.92 over the next 12 months. Extendicare Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Extendicare Inc is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Extendicare Inc’s stock price was CAD 10.54. Extendicare Inc’s stock price has changed by +2.93% over the past week, +14.32% over the past month and +50.36% over the last year.
No recent analyst target price found for Extendicare Inc
No recent average analyst rating found for Extendicare Inc
Company Overview Extendicare Inc
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties. It operates through the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. The company was incorporated in 1968 and is based in Markham, Canada. Address: 3000 Steeles Avenue East, Markham, ON, Canada, L3R 4T9 Read Less
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as...Read More
Frequently Asked Questions About Extendicare Inc (EXE:CA) Stock
Based on ratings from 3 analysts Extendicare Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has buy, sell and 5 hold ratings.
EXE:CA stock's dividend yield is 5.06%.
Our analysis grades EXE:CA stock's dividend yield at D+. This means that EXE:CA stock's dividend yield is above 67% of the stocks in the Medical Care Facilities sector in the TSX exchange.
Based on this EXE:CA may be a average dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for EXE:CA is CAD 9.92 over the next 12 months. The maximum analyst target price is CAD 11 while the minimum anlayst target price is CAD 9.
EXE:CA stock's Price/Earning ratio is 14.44.
Our analysis grades EXE:CA stock's Price / Earning ratio at A+. This means that EXE:CA stock's Price/Earning ratio is above 0% of the stocks in the Medical Care Facilities sector in the TSX exchange.
Based on this EXE:CA may be undervalued for its sector.
The last closing price of EXE:CA's stock was CAD 10.54.
The most recent market capitalization for EXE:CA is CAD 0.88B.
Based on targets from 3 analysts, the average taret price for EXE:CA is projected at CAD 9.92 over the next 12 months.
This means that EXE:CA's stock price may go down by -5.91% over the next 12 months.
We can't find any ETFs which contains Extendicare Inc's stock.
As per our most recent records Extendicare Inc has 0 Employees.
Extendicare Inc's registered address is 3000 Steeles Avenue East, Markham, ON, Canada, L3R 4T9.
You can get more information about it from Extendicare Inc's website at https://www.extendicare.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Extendicare Inc (EXE:CA) Stock
Based on ratings from 3 analysts Extendicare Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has buy, sell and 5 hold ratings.
EXE:CA stock's dividend yield is 5.06%.
Our analysis grades EXE:CA stock's dividend yield at D+. This means that EXE:CA stock's dividend yield is above 67% of the stocks in the Medical Care Facilities sector in the TSX exchange.
Based on this EXE:CA may be a average dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for EXE:CA is CAD 9.92 over the next 12 months. The maximum analyst target price is CAD 11 while the minimum anlayst target price is CAD 9.
EXE:CA stock's Price/Earning ratio is 14.44.
Our analysis grades EXE:CA stock's Price / Earning ratio at A+. This means that EXE:CA stock's Price/Earning ratio is above 0% of the stocks in the Medical Care Facilities sector in the TSX exchange.
Based on this EXE:CA may be undervalued for its sector.
The last closing price of EXE:CA's stock was CAD 10.54.
The most recent market capitalization for EXE:CA is CAD 0.88B.
Based on targets from 3 analysts, the average taret price for EXE:CA is projected at CAD 9.92 over the next 12 months.
This means that EXE:CA's stock price may go down by -5.91% over the next 12 months.
We can't find any ETFs which contains Extendicare Inc's stock.
As per our most recent records Extendicare Inc has 0 Employees.
Extendicare Inc's registered address is 3000 Steeles Avenue East, Markham, ON, Canada, L3R 4T9.
You can get more information about it from Extendicare Inc's website at https://www.extendicare.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EXE:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
